Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeligekimab in Moderate to Severe Palmoplantar Pustulosis
NCT07503652Phase 4Recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of xeligekimab in palmoplantar pustulosis (PPP), sponsored by First Hospital of China Medical University. Started Mar 2026; status: recruiting.
02
Drugs
xeligekimab
03
Conditions
palmoplantar pustulosis (PPP)
Beyond the preview
Go deeper on NCT07503652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07503652.